Therapeutic Areas: Otolaryngology (Ear, Nose, Throat) | Pulmonary/Respiratory Diseases | Immunology | Infections and Infectious Diseases
Allergy Clinical Trials
A listing of Allergy medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
California
Wildomar : Elite Clinical Trials, Inc.
Does Your Child Suffer from Allergies or Hives?
Riverside : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
San Jose : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Florida
Pensacola : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Georgia
Idaho
Indiana
Evansville : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Kentucky
Bowling Green : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Owensboro : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Minnesota
Minneapolis : Clinical Research Institute, MN
765 / 766 DUST MITE ALLERGY RESEARCH STUDY
Minneapolis : Clinical Research Institute, MN
767 / VOLUNTARY ADULT ASTHMA RESEARCH STUDY
Minneapolis : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Missouri
Creve Coeur : The Clinical Research Center, LLC
Do you suffer from Cat Allergies and live with a Cat? If so you may qualify for our cat allergy study.
St. Louis : Washington University in St. Louis - Center for Clinical Studies
Do you have an allergy to penicillin? Washington University seeks volunteers for a research study.
Nebraska
Papillion : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
New York
Bronx : The Harold & Muriel Block Institute for Clinical and Translational Research at Einstein & Montefiore Updated
Diagnosis of Aspirin Hypersensitivity by Measuring Arachidonic Acid Metabolites after Low Dose Aspirin Challenge
Mineola : Winthrop University Hospital Clinical Trials Center
Study for adults with Hereditary Angioedema (HAE)
Brooklyn : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
North Carolina
Raleigh : North Carolina Clinical Research
Allergies Got You Down?
Raleigh : North Carolina Clinical Research
Dust Mites and the Allergies they cause are in every room. Sneezing? Itchy Eyes? Stuffy Nose? There's room for you in our research study.
Ohio
Cincinnati : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Oregon
Medford : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Rhode Island
Lincoln : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
South Carolina
Summerville : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Utah
Canada
Montreal : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Ottawa : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Quebec : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
St-Charles-Borromée : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Czech Republic
Breclav : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Brno : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Kutna Hora : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Tabor : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Teplice : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Trutnov : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Denmark
Copenhagen : National University Hospital,
Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1
Finland
Helsinki : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Turku : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
France
Paris : Hotel Dieu Hospital
Diagnosis and Physiopathology of Insulin Allergy
Germany
Berlin : Hospital Charité
An Elimination Diet Using a New Amino Acid Based Formula: Immunological and Clinical Effects in Cow's Milk Allergy
Bonn : St.-Marien-Hospital
An Elimination Diet Using a New Amino Acid Based Formula: Immunological and Clinical Effects in Cow's Milk Allergy
Greece
Athens : University of Athens
Hydrolyzed Egg and Tolerance Induction
Hungary
Debrecen : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Israel
Haifa : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Jerusalem : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Kfar-Sava : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Rehovot : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Italy
Firenze : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Genova : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Padua : University Hospital of Padua
Hydrolyzed Egg and Tolerance Induction
Pisa : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Reggio Emilia : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Verona : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Korea, Republic of
Bucheon-Si : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Cheongju : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Seoul : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Suwon : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Poland
Bialystok : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Lodz : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Portugal
Porto : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Slovakia
Banska Bystrica : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Bratislava : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Bratislava : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Nitra : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Ruzomberok : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Trencin : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Spain
Madrid : Hospital Universitario de La Princesa
Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate
Manresa : H. Manresa
Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).
Sevilla : H. Virgen Macarena
Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).
Sevilla : H. Virgen del Rocío
Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).
Xativa : H. Luis Alcañiz
Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).
Switzerland
United Kingdom
Birmingham : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Bradford : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Dartford : NSHI Ltd
Glasgow Asthma and Allergy Study
East Yorkshire : Novartis Investigative Site
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
London : Evelina Children's Hospital - St Thomas' Hospital
An Elimination Diet Using a New Amino Acid Based Formula: Immunological and Clinical Effects in Cow's Milk Allergy
Newcastle upon Tyne : Newcastle general hospital
An Elimination Diet Using a New Amino Acid Based Formula: Immunological and Clinical Effects in Cow's Milk Allergy
Newport : David Hyde Allergy Clinic - St. Mary's hospital
An Elimination Diet Using a New Amino Acid Based Formula: Immunological and Clinical Effects in Cow's Milk Allergy
Southampton : Southampton General Hospital
An Elimination Diet Using a New Amino Acid Based Formula: Immunological and Clinical Effects in Cow's Milk Allergy